Cell Therapy and Myocardial Recovery in Heart Failure Patients Undergoing Left Ventricular Assist Device Support
The Effects of Cell Therapy on Myocardial Recovery in Chronic Heart Failure Patients Undergoing Left Ventricular Assist Device Support: A Pilot Trial (CELL-VAD Pilot)
University Medical Centre Ljubljana
10 participants
May 1, 2022
INTERVENTIONAL
Conditions
Summary
The goal of CELL-VAD Pilot trial is to investigate a personalized stem cell therapy approach for patients with advanced non-ischemic chronic heart failure (NICM) who are supported by LVAD. In the clinical trial, the investigators aim to enroll 10 patients with NICM, scheduled for LVAD implantation. After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization. All patients will then undergo autologous CD34+ cell therapy which will be intracoronaryly delivered to the target myocardium using NOGA electromechanical mapping system. All patients will be followed for 6 months after cell therapy. At baseline, and at 1, 3, and 6 months after cell therapy, the investigators will perform comprehensive clinical evaluation.
Eligibility
Inclusion Criteria5
- non-ischemic dilated cardiomyopathy
- patient accepted for LVAD support
- optimal (or maximal tolerable therapy) heart failure ≥ 2 months
- age 18-65 years
- ability to provide informed consent
Exclusion Criteria21
- ischemic cardiomyopathy
- Cardiomyopathy with a reversible cause that has not been treated e.g. thyroid disease, alcohol abuse, hypophosphataemia, hypocalcaemia, cocaine abuse, selenium toxicity \& chronic uncontrolled tachycardia.
- Cardiomyopathy in association with a neuromuscular disorder e.g. Duchenne's progressive muscular dystrophy.
- ongoing or recent (less than 1 month) infection
- acute multi-organ failure
- clinically significant anemia (Hb \< 10 g/dL)
- clinically significant leukopenia (L \< 2 x 109/L) or leukocytosis (L \> 14 x 109/L)
- clinically significant thrombocytopenia (TRC \< 50 x 109/L)
- known disorders of hemostasis that can not be corrected
- history of any thromboembolic complications
- chronic kidney disease (higher than stage III)
- chronic liver disease (Child B or C)
- diminished functional capacity for other reasons such as COPD, moderate or severe claudications, severe musculosceletal system pain or morbid obesity (BMI \> 35 kg/m2)
- aortic stenosis (AVA \< 1.3 cm2) or ocluded aortic valve
- artificial (mechanical or biological) aortic valve
- patients with reduced immune response
- history of limphoprolipherative disorders or malignancy within 5 years
- left ventricular thrombus
- participation in another interventional clinical trial
- life expectancy less than 12 months
- known hypersensitivity to DMSO, penicillin or streptomycin
Interventions
After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06154044